Two Lupus Therapeutics Studies Report Positive Results at 2019 ACR/ARP Annual Meeting
November 12, 2019 Two positive clinical studies presented at the 2019 ACR/ARP Annual Meeting were conducted through the Lupus Clinical Investigators Network (LuCIN) formed and managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance. Results of both studies hold promise to improve how physicians can better monitor lupus patients’ symptoms and disease activity. […]
LRA’s Visionary Strategy to Turn Lupus Complexity to its Cure
July 15, 2021 Dear Friends, With much excitement, we introduce our new overarching approach to fulfilling LRA’s mission: Turning Complexity to Cure. Our goal is to involve the lupus community and beyond in our strategy to turn the core problem of lupus – its heterogeneity – how much it differs from person to person – into its solution through […]
Existing Cancer Drug May Lower Inflammation in Autoimmune Diseases Like Lupus
December 14, 2020 In a recent study published in the Journal of Immunology, LRA-funded researcher Dr. John Zhang at Medical University of South Carolina found that a protein called Fli-1 causes immune cells to produce a molecule that causes inflammation. When Fli-1 was hindered by the chemotherapeutic drug camptothecin, immune cells produced fewer inflammatory molecules. […]
New CDC Study Estimates 204,295 Americans Have Lupus
January 29, 2021 According to a new analysis funded by the Centers for Disease Control and Prevention, about 204,295 Americans have systemic lupus erythematosus (SLE), based on strict criteria for diagnosis by the American College of Rheumatology. These data, however, do not include cutaneous lupus. Based on an analysis of five studies, the national estimate […]
The Lupus Research Alliance Partners with the National Kidney Foundation to Offer Course to Healthcare Professionals
November 12, 2019 The Lupus Research Alliance (LRA) is pleased to announce a new collaboration with the National Kidney Foundation (NKF) on a free course for healthcare professionals about ways to better diagnose, monitor and treat patients with systemic lupus erythematosus (SLE) and lupus nephritis. The online course is critically important because as the community […]
Top Research Needs to Help Kids with Lupus
July 5, 2019 A study published last week in Pediatric Rheumatology identified the top priorities for research into lupus in children. The survey asked pediatric rheumatologists, dermatologists and nephrologists with expertise in lupus to categorize areas of research into high, medium or low priority. The survey was given to pediatric rheumatologists, dermatologists and nephrologists with […]
Lupus Study Showed Vitamin D Did Not Improve Bone Health
September 19, 2019 A small clinical trial published in Lupus Science & Medicine found that taking vitamin D supplements did not improve bone health for people with lupus. Conducted by several lupus experts throughout the U.S., the study looked at the effect of vitamin D supplements on changes in bone turnover markers that indicate changes […]
Lupus News Corner
BIG … BOLD … IDEAS ARE TRANSFORMING LUPUS RESEARCH—thanks to people like you! Thanks to our remarkable supporters, the Lupus Research Alliance awarded nearly $7.5 million through the following grant mechanisms in 2019: 2019 Novel Research Grants ($1,798,602) Carla Cuda, PhD The Role of Microglial Subsets in Driving Neuropsychiatric Symptoms of SLE Northwestern University – Chicago […]
LuCIN FAQ
Frequently Asked Questions About the Lupus Clinical Investigators Network (LuCIN) Clinical Research Program About LuCIN 1. What is LuCIN? Lupus Clinical Investigators Network (LuCIN) is a Lupus clinical trials network, made up of 57 of the most prestigious academic research medical centers throughout North America. Founded and sponsored by the Lupus Research Alliance, LuCIN brings […]
Positive Research Results on Potential Lupus Treatments Shared at Major Medical Meeting
June 8, 2021 The annual European Congress of Rheumatology (EULAR 2021) brought much good news of potential new treatments for systemic lupus erythematosus (SLE). Following are highlights: Rituximab Plus Belimumab Taking belimumab after rituximab may help lupus according to data from the BEAT-LUPUS trial presented at the 2021 EULAR Virtual Congress by the trial lead investigator […]
Stelara® and Olumiant® Considered Promising by Lupus Expert
February 19, 2019 In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided an overview of potential lupus therapies in development. He highlighted ustekinumab (brand name Stelara®) and baricitinib (brand name Olumiant®) as two drugs that look particularly promising. “The phase 2 extra-renal trial of baricitinib looks good; […]
LRA Congratulates Equillium on Positive Results of Study of Potential New Lupus Treatment
March 30, 2021 Equillium, Inc. announced positive topline data from the phase 1b EQUALISE study in patients with systemic lupus erythematosus (SLE). This study suggests that itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated among people with SLE. [Source: Equillium, Inc. Press Release 3.30.21] The EQUALISE study is evaluating […]